Free Trial
NASDAQ:PRLD

Prelude Therapeutics (PRLD) Stock Price, News & Analysis

Prelude Therapeutics logo
$0.81 +0.01 (+1.25%)
As of 07/3/2025 02:45 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Prelude Therapeutics Stock (NASDAQ:PRLD)

Key Stats

Today's Range
$0.78
$0.82
50-Day Range
$0.76
$1.18
52-Week Range
$0.61
$6.80
Volume
87,143 shs
Average Volume
292,016 shs
Market Capitalization
$45.73 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.50
Consensus Rating
Buy

Company Overview

Prelude Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
69th Percentile Overall Score

PRLD MarketRank™: 

Prelude Therapeutics scored higher than 69% of companies evaluated by MarketBeat, and ranked 300th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Prelude Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Prelude Therapeutics has only been the subject of 2 research reports in the past 90 days.

  • Read more about Prelude Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Prelude Therapeutics are expected to remain at ($1.81) per share in the coming year.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Prelude Therapeutics is -0.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Prelude Therapeutics is -0.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Prelude Therapeutics has a P/B Ratio of 0.34. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Prelude Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    3.45% of the float of Prelude Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Prelude Therapeutics has a short interest ratio ("days to cover") of 4.7.
  • Change versus previous month

    Short interest in Prelude Therapeutics has recently decreased by 11.07%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Prelude Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Prelude Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    3.45% of the float of Prelude Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Prelude Therapeutics has a short interest ratio ("days to cover") of 4.7.
  • Change versus previous month

    Short interest in Prelude Therapeutics has recently decreased by 11.07%, indicating that investor sentiment is improving significantly.
    • Insider Buying vs. Insider Selling

      In the past three months, Prelude Therapeutics insiders have not sold or bought any company stock.

    • Percentage Held by Insiders

      63.90% of the stock of Prelude Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

    • Percentage Held by Institutions

      79.72% of the stock of Prelude Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

    • Read more about Prelude Therapeutics' insider trading history.
    Receive PRLD Stock News and Ratings via Email

    Sign-up to receive the latest news and ratings for Prelude Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

    PRLD Stock News Headlines

    Trump’s treachery
    Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
    See More Headlines

    PRLD Stock Analysis - Frequently Asked Questions

    Prelude Therapeutics' stock was trading at $1.2750 at the start of the year. Since then, PRLD stock has decreased by 36.5% and is now trading at $0.81.

    Prelude Therapeutics Incorporated (NASDAQ:PRLD) announced its quarterly earnings results on Tuesday, May, 6th. The company reported ($0.42) earnings per share for the quarter, beating the consensus estimate of ($0.47) by $0.05.

    Prelude Therapeutics (PRLD) raised $149 million in an initial public offering on Friday, September 25th 2020. The company issued 8,300,000 shares at $17.00-$19.00 per share. Morgan Stanley, Goldman Sachs and BofA Securities acted as the underwriters for the IPO.

    Shares of PRLD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

    Based on aggregate information from My MarketBeat watchlists, some other companies that Prelude Therapeutics investors own include Tesla (TSLA), Netflix (NFLX), NVIDIA (NVDA), JPMorgan Chase & Co. (JPM), Meta Platforms (META), Visa (V) and Advanced Micro Devices (AMD).

    Company Calendar

    Last Earnings
    5/06/2025
    Today
    7/06/2025
    Next Earnings (Estimated)
    8/11/2025
    Fiscal Year End
    12/31/2025

    Industry, Sector and Symbol

    Stock Exchange
    NASDAQ
    Sector
    Medical
    Industry
    MED - DRUGS
    Sub-Industry
    Pharmaceutical Products
    Current Symbol
    NASDAQ:PRLD
    Fax
    N/A
    Employees
    120
    Year Founded
    N/A

    Price Target and Rating

    Average Stock Price Target
    $4.50
    High Stock Price Target
    $5.00
    Low Stock Price Target
    $4.00
    Potential Upside/Downside
    +455.6%
    Consensus Rating
    Buy
    Rating Score (0-4)
    3.00
    Research Coverage
    2 Analysts

    Profitability

    Trailing P/E Ratio
    N/A
    Forward P/E Ratio
    N/A
    P/E Growth
    N/A
    Net Income
    -$127.17 million
    Pretax Margin
    -1,826.10%

    Debt

    Sales & Book Value

    Annual Sales
    $7 million
    Price / Cash Flow
    N/A
    Book Value
    $2.39 per share
    Price / Book
    0.34

    Miscellaneous

    Free Float
    20,382,000
    Market Cap
    $45.73 million
    Optionable
    Optionable
    Beta
    1.22
    10 Best Cheap Stocks to Buy Now Cover

    MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

    Get This Free Report

    This page (NASDAQ:PRLD) was last updated on 7/6/2025 by MarketBeat.com Staff
    From Our Partners